

TABLE OF CONTENTS

July 21, 2008

No. 2099

BUSINESS

- 1 Ferring Accelerates Business Development in Japan Aiming at ¥30 Bil. Sales in 2017
- OD Tablets of Desmopressin under Development
- Aiming at Becoming Market Leader in Defined Therapeutic Areas
- 3 Daiichi Sankyo Enters ¥88 Bil. Market for NSAID Tapes with Loxonin
- 3 Nippon Kayaku to Actively Invest in Macromolecular Anticancer Agents
- 4 Ranbaxy Categorically Denies Allegations
- 4 *Koroshō* to Investigate Price Agreement Rate as of End of June
- 5 Ain Pharmaciez to Achieve 90% Price Agreement Rate by End of July
- 5 Takeda Applies for Mutual Agreement Procedure to Resolve Double Taxation
- 6 **BUSINESS NEWS IN BRIEF**
- Eisai Starts Marketing ALOXI for PONV in the US
- Daiichi Sankyo, Lead Chemical: Loxonin Tape
- 6 **NEW PRODUCT**
- Daiichi Sankyo Licenses Venofer to Fresenius Medical Care in the US

REGULATORY

- 8 Industry Needs to Present More Data on Reform Proposed by It
- 8 FPAMJ's Proposal Meets Harsh Opposition at *Chuikyo*
- 9 *Chuikyo* to Conduct Survey to Verify Effects of FY2008 Medical Fee Revision
- 9 *Koroshō* Takes into Account US Opposition to More Frequent Drug Price Revisions
- 10 **REGULATORY NEWS IN BRIEF**
- *Koroshō* to Increase Staff Responsible for Safety Measures to 300
- Influenza Vaccine Reserves for 50% of the Population Needed
- 11 **Commentary**
- Industry Needs More Creative Thinking: NHI Pricing System Reform

MEDICAL DEVICES

- 10 **MEDICAL DEVICE NEWS IN BRIEF**
- Shionogi's Allerport TARC Permitted for Reimbursement

R&D

- 12 Kyowa Hakko Starts Developing siRNA Drugs in Earnest
- 12 Daiichi Sankyo to Collaborate with Seattle Genetics to Develop ADC Drugs

- 13 *Koroshō* Calls For Commercialization of Cures of Alzheimer's Disease in 10 Years
- 13 *Koroshō* Gives Up Development of 2 Unapproved Drugs
- 14 **R&D NEWS IN BRIEF**
- Glycomedics Considers Alliance for Flu Inhibitor
- Fuso, Oncotherapy Science to Enter PII for OTS102
- Takara Bio to Accelerate Research in Gene Medicine
- Roche Develops 3rd Generation Anti-CD-20 Antibody GA101

GENERICS

- 15 *Koroshō* Tests Purity of Generics of 10 APIs
- 15 OHARA Aims at Sales of ¥700 Mil. with Amlodipine Generics in FY2009
- 14 **GENERICS NEWS IN BRIEF**
- TanabeSeiyakuHanbai Launches Generics of 9 APIs
- KYORIN Rimedio Launches Generics of 3 APIs
- *Koroshō* to More Strictly Inspect Quality of Generics
- *Koroshō* Welcomes Entry of Foreign-Affiliated Companies into Market for Generics

SELF-MEDICATION

- 16 New OTC Drug Sales System Ready to Go
- 17 *Koroshō*'s Draft Report on the Fence Re Qualification of Store Managers
- NMRA Opposes to Use of Non-Pharmacists as Managers of Stores Selling Class 1 OTC Drugs
- JPA to Call on Makers to Label Class 1 OTC Drugs as "Pharmacists' Drugs"
- 17 Switch OTC Drugs Hold Key to Market Revitalization
- Amended PAL Should Stimulate Market for OTC Drugs When Amended PAL Is Fully Implemented

MEDICAL FACILITIES & NURSING CARE

- 18 Use of Tamiflu Not Correlated with Abnormal Behavior: *Koroshō* Working Group
- 18 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
- QOL Is Improved with Combination Antihypertensive Agents
- Prostate-Specific Antigen Testing should Be Promoted
- Temporary Use of Insulin at Early Stage Protects Pancreas